Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.
Please consider a small donation if you think this website provides you with relevant information
| Date | Title | Source |
|---|---|---|
| 2024-03-01 5:31:2 am | Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories | GlobeNewsWire |
| 2024-02-28 9:0:9 am | Kinnate Biopharma Inc. (KNTE) Upgraded to Buy: What Does It Mean for the Stock? | Zacks |
| 2024-02-17 6:22:4 am | Private equity firms who hold 45% of Kinnate Biopharma Inc. (NASDAQ:KNTE) gained 11%, institutions profited as well | Simply Wall St. |
| 2024-02-16 5:0:0 am | XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right | GlobeNewswire |
| 2024-02-16 5:0:0 am | Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share | GlobeNewswire |
| 2023-12-06 8:55:34 am | 13 Hot Penny Stocks To Buy According to Hedge Funds | Insider Monkey |
Please consider a small donation if you think this website provides you with relevant information